Statements (28)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:monoclonal_antibody
|
| gptkbp:administeredBy |
intravenous infusion
|
| gptkbp:approvedBy |
gptkb:FDA
2021 |
| gptkbp:ATCCode |
J06BD09
|
| gptkbp:brand |
gptkb:Xevudy
|
| gptkbp:CASNumber |
2471911-97-8
|
| gptkbp:developedBy |
gptkb:Vir_Biotechnology
GlaxoSmithKline |
| gptkbp:halfLife |
~49 days
|
| gptkbp:hasMolecularFormula |
C6488H9996N1724O2026S44
|
| https://www.w3.org/2000/01/rdf-schema#label |
sotrovimab
|
| gptkbp:indication |
high risk of progression to severe COVID-19
mild-to-moderate COVID-19 |
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
neutralizes SARS-CoV-2
|
| gptkbp:notRecommendedFor |
hospitalized patients requiring oxygen
|
| gptkbp:routeOfAdministration |
intravenous
|
| gptkbp:sideEffect |
diarrhea
rash allergic reactions infusion-related reactions |
| gptkbp:target |
gptkb:SARS-CoV-2_spike_protein
|
| gptkbp:UNII |
6QY1D9K2F1
|
| gptkbp:usedFor |
gptkb:COVID-19
|
| gptkbp:WHOEML |
yes
|
| gptkbp:bfsParent |
gptkb:NASDAQ:VIR
|
| gptkbp:bfsLayer |
7
|